Project Grant R00HL168434
Award Date
7/1/25
Completion Date
5/31/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $507,096.00 to Wake Forest University Health Sciences to conduct research on the role of mitochondrial calcium signaling in heart failure with preserved ejection fraction (HFPEF). The key objectives are to: Characterize heart cell-specific mitochondrial calcium signaling and functions in HFPEF mouse models, 2) Evaluate the effects...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,236 to The University of Iowa to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The goal is to evaluate how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium concentration, plasma osmolality, regional sympathetic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This federal Project Grant award, totaling $2,158,428 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at investigating the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in mediating hypertension and vascular remodeling. The award supports three specific aims: 1) Studying the involvement of PKM2 activation in vascular smooth muscle cells (VSMCs) in hypertension and vascular...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the biomechanical mechanisms underlying right ventricular (RV) dysfunction and ventricular-arterial uncoupling in pulmonary hypertension. The $642,045 award to the Texas A&M Engineering Experiment Station (Tees) aims to: 1) determine how passive remodeling of the RV free wall competes with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $542,663.00 to Texas A&M University System Health Science Center to conduct research on the role of small GTPase RhoE in post-myocardial infarction cardiac fibrotic remodeling. The goal is to explore how early activation of adaptive anti-fibrotic signals mediated by RhoE can offer cardiac protection during the remodeling process after a heart attack....
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $655,636 in funding to the Texas Heart Institute (THI) to investigate the role of cardiac fibroblasts in the development of heart failure in patients with single ventricle congenital heart disease. The objectives are to gain insights into the intrinsic molecular mechanisms that promote cellular senescence, metabolic remodeling, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to develop an integrated super-resolution cardiac magnetic resonance imaging and deep learning (CMR-DL) technology to isolate and quantify the contributions of passive and active remodeling events to left ventricular diastolic dysfunction (LVDD). The total award amount is $702,534, with a project period from March 6, 2025 to December 31, 2029. The awardee,...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...